BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week...
January 07 2020 - 1:00AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading
developer of adult stem cell therapeutics for neurodegenerative
diseases, announced today that Chaim Lebovits, President and Chief
Executive Officer, will provide a corporate overview at the 2020
Biotech Showcase, being held on January 13-15, 2020 at the Hilton
San Francisco Union Square in San Francisco, California.
Mr. Lebovits will also present at the 3rd Annual
Neuroscience Innovation Forum, taking place on January 12, 2020, at
the Marines’ Memorial Club in San Francisco. Additionally, Ralph
Kern M.D., MHSc, BrainStorm’s Chief Operating Officer and Chief
Medical Officer, will participate on a Rare & Orphan
Diseases Panel.
2020
Biotech Showcase |
Details |
Date: |
Monday, January 13, 2020 |
Time: |
11:00 am Pacific Time |
Location: |
Hilton San Francisco Union Square, Hilton/Yosemite A, Ballroom
Level |
Presenter: |
Chaim Lebovits, CEO |
Webcast: |
https://bit.ly/37EfFfC |
3nd
Annual Neuroscience Innovation
Forum |
Details: |
Company
Presentation: |
|
Date: |
Sunday, January 12, 2020 |
Time: |
2:10 pm Pacific Time |
Location: |
Marines’ Memorial Club, SF |
Presenter: |
Chaim Lebovits, CEO |
Webcast: |
https://bit.ly/2T4ZeFj |
Rare
& Orphan Disease Panel: |
Details |
Date: |
Sunday, January 12, 2020 |
Time: |
10:45 am Pacific Time |
Location: |
Marines’ Memorial Club, SF |
Presenter: |
Dr. Ralph Kern, COO & CMO |
Meetings
BrainStorm’s senior management will also be
hosting institutional investor and partnering meetings at the 2020
Biotech Showcase conference (https://goo.gl/SGFm62). Please use the
Investor contact information provided below to schedule a
meeting.
About NurOwn®
NurOwn® (autologous MSC-NTF cells) represent a
promising investigational approach to targeting disease pathways
important in neurodegenerative disorders. MSC-NTF cells are
produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. NurOwn® is
currently being evaluated in a Phase 3 ALS randomized
placebo-controlled trial and in a Phase 2 open-label multicenter
trial in Progressive MS.
About BrainStorm Cell Therapeutics
Inc.
BrainStorm Cell Therapeutics Inc. is a leading
developer of innovative autologous adult stem cell therapeutics for
debilitating neurodegenerative diseases. The Company holds the
rights to clinical development and commercialization of the NurOwn®
technology platform used to produce autologous MSC-NTF cells
through an exclusive, worldwide licensing agreement. Autologous
MSC-NTF cells have received Orphan Drug status designation from the
U.S. Food and Drug Administration (U.S. FDA) and the European
Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a
Phase 3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute for
Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is
intended to support a filing for U.S. FDA approval of autologous
MSC-NTF cells in ALS. For more information, visit BrainStorm's
website at www.brainstorm-cell.com.
Safe-Harbor
Statement
Statements in this announcement other than
historical data and information, including statements regarding
future clinical trial enrollment and data, constitute
"forward-looking statements" and involve risks and uncertainties
that could cause BrainStorm Cell Therapeutics
Inc.'s actual results to differ materially from those stated
or implied by such forward-looking statements. Terms and phrases
such as "may", "should", "would", "could", "will", "expect",
"likely", "believe", "plan", "estimate", "predict", "potential",
and similar terms and phrases are intended to identify these
forward-looking statements. The potential risks and uncertainties
include, without limitation, BrainStorm’s need to raise additional
capital, BrainStorm’s ability to continue as a going concern,
regulatory approval of BrainStorm’s NurOwn® treatment candidate,
the success of BrainStorm’s product development programs and
research, regulatory and personnel issues, development of a global
market for our services, the ability to secure and maintain
research institutions to conduct our clinical trials, the ability
to generate significant revenue, the ability of BrainStorm’s
NurOwn® treatment candidate to achieve broad acceptance as a
treatment option for ALS or other neurodegenerative diseases,
BrainStorm’s ability to manufacture and commercialize the NurOwn®
treatment candidate, obtaining patents that provide meaningful
protection, competition and market developments, BrainStorm’s
ability to protect our intellectual property from infringement by
third parties, heath reform legislation, demand for our services,
currency exchange rates and product liability claims and
litigation,; and other factors detailed in BrainStorm's annual
report on Form 10-K and quarterly reports on Form 10-Q available
at http://www.sec.gov. These factors should be considered
carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the
beliefs, expectations and opinions of management as of the date of
this press release. We do not assume any obligation to update
forward-looking statements to reflect actual results or assumptions
if circumstances or management's beliefs, expectations or opinions
should change, unless otherwise required by law. Although we
believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results,
levels of activity, performance or achievements.
CONTACTS
Corporate: Uri
Yablonka Chief Business Officer BrainStorm Cell
Therapeutics Inc. Phone: 646-666-3188
uri@brainstorm-cell.com
Media: Sean Leous Westwicke/ICR
PR Phone: +1.646.677.1839 sean.leous@icrinc.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Sep 2023 to Sep 2024